Navigation Links
OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
Date:10/13/2008

ons that could cause actual results to differ materially from those described in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. For example, statements of the Company's ability to gain FDA agreement on protocol design and time frames to do so, the strength of the combined oncology product pipeline, the timing of clinical trials and development efforts and the results of clinical and pre-clinical studies are all forward-looking statements. The potential risks and uncertainties include, among others, the possibility that an agreement with FDA cannot be reached regarding a clinical trial using pain as the primary endpoint for OGX-011, the timing and costs of clinical trials and regulatory approvals, risks that clinical trials will not be successful or confirm earlier clinical trial results, risks associated with obtaining funding from third parties or completing a financing necessary to support the costs and expenses of clinical studies as well as research and development activities, as well as other risks relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products. A more complete discussion of risks and uncertainties that may affect forward-looking statements is included in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for fiscal year 2007, and its Quarterly Report on Form 10-Q for the second quarter of 2008. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of the Company. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
2. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
3. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
4. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. OncoGenex increases economic interest in lead cancer drug OGX-011
7. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
8. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
9. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
10. Prominent Physician Achieves Success Using Topical Sinus Medications via Pulsitile Irrigation
11. Realtime Achieves ISO 13485:2003 Certification Targeting BioTech Quality Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... number of significant technological challenges in their quest ... created for the James Webb Space Telescope. , ... a scientist at NASA,s Goddard Space Flight Center ... microshutter arrays that is, those activated by ... as the current technology,s magnetically activated arrays. This ...
(Date:7/29/2014)... Bellingham, WA (PRWEB) July 29, 2014 ... manipulation of the brain that are driving a revolution ... a new peer-reviewed journal published by SPIE, ... The first issue coincides with the launch of the ... section features articles that lay out a vision for ...
(Date:7/29/2014)...   Sequenom, Inc. (NASDAQ: SQNM ... analysis solutions, and Mayo Medical Laboratories (MML), ... the United States , have announced a ... "We have great appreciation for Mayo Clinic,s ... welcome the opportunity to partner with the organization,s leading ...
(Date:7/29/2014)... July 29, 2014 Human Longevity, Inc. (HLI), ... focused on extending the healthy, high performance human life ... , Ph.D., an expert in machine learning and machine ... to HLI from Google where he was Distinguished Research ... report directly to HLI Co-Founder and CEO, J. ...
Breaking Biology Technology:Revolutionary microshutter technology hurdles significant challenges 2Revolutionary microshutter technology hurdles significant challenges 3Revolutionary microshutter technology hurdles significant challenges 4SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 2SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 3SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 4Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3
... do Dr. Peper, Dr. Sigmund Freud and Arnold Schwarzenegger ... be surprised to learn that Europeans love Dr. Peper. ... Erik Peper, President of the Biofeedback Foundation of Europe ... Dr. Erik Peper opens the 13th Annual Conference of ...
... Presents on Therapy Development StrategyCAMBRIDGE, Mass., Feb. 17 ... has announced the 2009 launch of its popular ... seminar is designed to inform and update patients, ... to discover and develop effective treatments for amyotrophic ...
... Inc. (OTC Bulletin Board: GNPH) ("Genesis" or the,"Company"), a ... Republic of China, today announced its financial results for ... 31, 2008. , , Second Quarter ... Revenue was $32.9 million, up 24.1% from the corresponding ...
Cached Biology Technology:Dr. Peper, Dr. Freud and Arnold Schwarzenegger 2Seminar Will Bring ALS Researchers to Patient Groups 2Seminar Will Bring ALS Researchers to Patient Groups 3Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 2Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 3Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 4Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 5Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 6Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 7Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 8Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 9Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 10Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 11Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 12Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 13Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 14Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 15Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 16
(Date:7/29/2014)... by academics in the University of Bristol,s Nutrition and ... liquid calories into account when planning meals. , The ... Study of Ingestive Behavior Conference (SSIB 2014) in Seattle, ... that we do. , The team was led by ... of Experimental Psychology. , As part of a Biotechnology ...
(Date:7/29/2014)... methods and applications for imaging and manipulation of the ... were the inspiration behind Neurophotonics , a new ... optics and photonics. , The first issue coincides with ... States, and a special section features articles that lay ... impact that optics and photonics will have on advancing ...
(Date:7/29/2014)... warms and sea ice retreats, the North is changing. ... open water which is predicted to extend across the ... Storms thus have the potential to create Arctic swell ... unpredictable element to the region. , A University of Washington ... middle of the Arctic Ocean, and detected house-sized waves ...
Breaking Biology News(10 mins):SPIE launches Neurophotonics journal with special section on BRAIN Initiative 2SPIE launches Neurophotonics journal with special section on BRAIN Initiative 3Huge waves measured for first time in Arctic Ocean 2Huge waves measured for first time in Arctic Ocean 3
... at the National Institute of Allergy and Infectious Disease ... (NIH), have identified a critical human cell surface molecule ... virus that causes Kaposi's sarcoma and certain forms of ... HIV/AIDS, and it typically manifests as multiple purple-hued skin ...
... of extra genes gave fish on separate continents the ... University of Texas at Austin. , Dr. Harold Zakon ... of the National Academy of Sciences, show that African ... organs by modifying sodium channel proteins typically used in ...
... in the brain may unlock the mystery behind the ... issue of Cell. Hibernation allows animals from bears to ... the harshest of winter conditions. , If the findings ... first essential brain signal governing the seasonal adaptation, according ...
Cached Biology News:Landmark discovery of a Kaposi's sarcoma-associated herpesvirus receptor 2Landmark discovery of a Kaposi's sarcoma-associated herpesvirus receptor 3Convergent evolution of molecules in electric fish 2Possible brain hormone may unlock mystery of hibernation 2Possible brain hormone may unlock mystery of hibernation 3
... Avian Myeloblastosis Virus Reverse Transcriptase (AMV ... template DNA, RNA or RNA:DNA hybrids (1). ... more efficient than RNA primers) as well ... an intrinsic RNase H activity. Both nonionic ...
DNase I (Deoxyribonuclease I) digests single- and double-stranded DNA to oligodeoxyribonucleotides. Ribonuclease activity has been reduced to non-detectable levels....
... RQ1 RNase-Free DNase is a preparation ... or double-stranded DNA to produce 3-hydroxyl ... use in applications where maintaining the ... DNase is qualified for use with ...
... I, Wild Type Liquid. In 100 ... 200 µM EDTA, 20% glycerol, pH 7.9. AVOID ... is a monomeric protein of 765 amino acids ... relaxation of both positive and negative supercoiled DNAs ...
Biology Products: